Study of JK06 in Patients with Unresectable Locally Advanced or Metastatic Cancer

Salubris Biotherapeutics

Status and phase: Enrolling; Phase 2; Phase 1

Conditions: Solid Tumor

Treatments: Drug: JK06

Study type: Interventional

Funder types: Industry

Identifiers

NCT06667960

JK06.1.01

Details and patient eligibility

About

This is a Phase 1/2, open-label, multi-center, first-in-human, dose escalation and cohort expansion study evaluating multiple doses and schedules of intravenously administered JK06 in patients with unresectable locally, advanced or metastatic cancer.

Full description

This Phase 1/2, open label, dose escalation and cohort expansion study is designed to evaluate and characterize the safety, tolerability, PK, pharmacodynamics, immunogenicity, and preliminary anti-tumor activity of JK06 administered intravenously (IV) in patients with unresectable, locally advanced, or metastatic cancer. The study consists of a Dose Escalation phase to determine the MTD/recommended phase 2 dose (RP2D) of JK06, followed by a Cohort Expansion phase to further define the safety and initial efficacy of JK06 in tumor specific cohorts.

Enrollment: 155 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 1. Age ≥ 18 years old. 2. Signed informed consent and willing and able to comply with study procedures and scheduled visits.

  2. For Dose Escalation, patients with histologically diagnosed unresectable, locally advanced, or metastatic solid tumors.

  3. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1. 5. Life expectancy ≥ 12 weeks. 6. Measurable disease as per RECIST 1.1 criteria and documented by CT and/or MRI.

Note: lesions treated previously with radiation must demonstrate clear evidence of radiographic progression since the completion of prior radiotherapy and prior to study enrollment.

7. Acceptable laboratory parameters:

• Albumin ≥ 2.8 g/dL.

• Platelet count ≥ 100, 000.

• Hemoglobin ≥ 9.0 g/dL.

• Absolute neutrophil count ≥ 1,500/μL.

• ALT/AST ≤ 3.0 times ULN.

  • ALT/AST ≤ 5 × ULN for patients with liver metastases.

• Total bilirubin ≤ 1.5 ULN or ≤ 3 x ULN for patients with Gilbert's disease.

• Direct bilirubin ≤ 1.5 ULN for patients with total bilirubin > 1.5 ULN.

• Creatinine ≤ 1.8 mg/dL.

  • Or calculated/measured creatinine clearance > 30 mL/minute. 8. Identification of an archival tumor sample (i.e., tissue block (formalin-fixed paraffin-embedded [FFPE]) or a series of approximately 10-15 slides).

    9. Consent to pre-treatment fresh tumor biopsy for patients enrolled in the back-fill part of Dose Escalation and all eligible patients enrolled in Cohort Expansion.

    10. Women of childbearing potential (WOCBP) not surgically sterilized and between menarche and 1 year post menopause must have a negative serum or urine pregnancy test.

    11. Treated central nervous system (CNS) metastases 12. Must be willing and able to comply with clinic visits and procedures outlined in the study protocol.

    12. Concurrent use of hormones for breast cancer or for non-cancer related conditions (e.g., insulin for diabetes, hormone replacement therapy) is acceptable. Bisphosphonates or RANK-L inhibitors or analogues are permitted for supportive care of patients with bone metastases.

Exclusion criteria

1. Patients with symptomatic or unstable CNS primary tumor or metastases and/or carcinomatous meningitis. Patients with documented treated CNS metastases stable for at least 4 weeks may be enrolled at the discretion of the investigator.

2. Major surgery within 6 weeks from treatment initiation.

3. Clinically significant cardiovascular/vascular disease ≤ 6 months before first dose.

4. Clinically significant gastrointestinal disorders.

5. Clinically significant pulmonary compromise requiring supplemental oxygen use.

6. Grade 2 or greater peripheral neuropathy at time of study entry.

7. Vaccination with any live virus vaccine within 4 weeks prior to the initiation of study drug administration. Inactivated annual influenza vaccination is allowed.

8. Known hypersensitivity to JK06 or any excipient.

9. Second primary invasive malignancy not in remission for ≥ 1 year. Exceptions include non-melanoma skin cancer, cervical carcinoma in situ, resected melanoma in situ, or any malignancy considered to be indolent and never required therapy.

10. Any serious underlying medical or psychiatric condition that would preclude understanding and rendering of informed consent or impair the ability of the patient to receive or tolerate the planned treatment.

11. Recent or ongoing serious infection.

12. Prior systemic anti-cancer treatment:

    • For cytotoxic chemotherapy, small molecule inhibitors, radiation, or similar investigational treatments, ≤ 2 weeks or 5 half-lives, whichever is shorter.
    • For monoclonal antibodies or similar experimental therapies: ≤ 3 weeks or 5 half-lives, whichever is shorter.
    • Antibody drug conjugates and radioimmunoconjugates or other similar experimental therapies ≤ 6 weeks or 5 half-lives, whichever is shorter.

13. Ascites or pleural effusions requiring large volume para- or pleurocentesis within 4 weeks of treatment initiation.

14. Pregnant or nursing.

15. Therapeutic anticoagulation for a thromboembolic event that occurred within 3 months of dosing; prophylactic anticoagulation is permitted.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Sequential Assignment

Masking: None (Open label)

---

155 participants in 2 patient groups

Dose Escalation

Experimental group

Description:

Escalating repeated doses of JK06 administered intravenously. A cycle of treatment is defined as 21 days.

Treatment:

Drug: JK06

Dose Expansion

Experimental group

Description:

The RP2D/OBD of JK06 determined by the Escalation arm. A cycle of treatment is defined as 21 days.

Treatment:

Drug: JK06